about
Tackling a novel lethal virus: a focus on H7N9 vaccine development.Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.H7N9 Live Attenuated Influenza Vaccine Is Highly Immunogenic, Prevents Virus Replication, and Protects Against Severe Bronchopneumonia in Ferrets.Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers.Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.Immunogenicity and Cross Protection in Mice Afforded by Pandemic H1N1 Live Attenuated Influenza Vaccine Containing Wild-Type Nucleoprotein.Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model.Genotyping assay for differentiation of wild-type and vaccine viruses in subjects immunized with live attenuated influenza vaccine.Use of live attenuated influenza vaccines in young children in resource-poor settings.Analysis of Immune Epitopes of Respiratory Syncytial Virus for Designing of Vectored Vaccines Based on Influenza Virus Platform.Cold-adapted influenza viruses as a promising platform for viral-vector vaccines.Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine.Contribution of neuraminidase of influenza viruses to the sensitivity to sera inhibitors and reassortment efficiencyH7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus.Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2).Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets.Live Attenuated Influenza Vaccines engineered to express the nucleoprotein of a recent isolate stimulate human influenza CD8+ T cells more relevant to current infections.Reassortant viruses for influenza vaccines: is it time to reconsider their genome structures?H7N9: can H7N3 live-attenuated influenza vaccine be used at the early stage of the pandemic?Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated influenza vaccine expressing chimeric hemagglutinin.Basics of CD8 T-cell immune responses after influenza infection and vaccination with inactivated or live attenuated influenza vaccineTwo Live Attenuated Vaccines against Recent Low⁻and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in FerretsLive attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage siteM2e-based universal influenza vaccines: a historical overview and new approaches to developmentSequential Immunization with Universal Live Attenuated Influenza Vaccine Candidates Protects Ferrets against a High-Dose Heterologous Virus ChallengeRecombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory diseaseInsights into current clinical research on the immunogenicity of live attenuated influenza vaccinesOverview of human rhinovirus immunogenic epitopes for rational vaccine designRecombinant Live Attenuated Influenza Vaccine Viruses Carrying Conserved T-cell Epitopes of Human Adenoviruses Induce Functional Cytotoxic T-Cell Responses and Protect Mice against Both InfectionsA Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults
P50
Q30148631-78A13016-78CE-4FD4-BE68-9C88AD5F7A3BQ30151807-2A0F5757-30DC-4E9C-A113-54813916A65EQ30196901-68DF6EBA-151D-4474-BCEE-E25EA37FF502Q30205252-CB46A111-02A4-4F11-B2EF-D98DE739E91AQ30359013-192DA7D6-D386-48FE-97AF-6E7B8E91B0B8Q30360436-DC30B2ED-FD89-4C60-BCB7-B3EBD7B10678Q30365079-CC46410F-632E-4D8E-B45F-49BC819192AAQ30373298-9AA898A7-DDEC-4F3A-A1F9-97BCD9F39C1EQ30378132-3C9131E8-7F1C-4391-AFB5-80D4789A9DB1Q30378132-7350F2FB-7577-49D5-80A4-4ED6B484B3D1Q30379886-24FEF04B-523E-4163-BF39-3F6883697691Q30382548-59DE28FC-A816-4D9E-BDAC-3EC1FA9DA7AEQ30382809-67FF9519-C285-459B-9518-3AE33E585042Q30398731-1515D555-F8B4-4A1D-B19C-B56959C5AA7DQ37452408-A0818966-15F0-4ED2-A3A2-BCEAE9CCF923Q40131850-F2A6A879-DE67-42F7-87B0-10116E0F318DQ40539696-5B6876AB-91C6-422A-A2E9-5C9DC62FF716Q40596242-5676C6BC-8D0C-4C8F-B096-D5B7D9158A9FQ40664205-F51A45EB-02B7-450C-81DD-CA5F9EFB8F84Q41635120-854AA03F-DADF-44FC-82E8-BA3AC5F44239Q42199354-E3FED2CD-6F4D-4FA5-9F35-ABAC3162806BQ42273410-D612CE53-9197-433F-8F41-69EA8C905609Q43173226-FCE21156-F598-4C4A-9C7C-E886BC4FB988Q44943273-C2546BE0-BA84-41A6-A973-A12AF2D16E55Q47281607-1C903F5C-8846-44EC-A79B-D8A4A3E32EC4Q50890564-87D05BBF-0A0A-445A-8020-1E81E05AB8EEQ50890564-D6CEDF02-561E-455A-9517-AA9C6456DC35Q51856923-ED3D129F-65CD-4A19-8A3E-5160C96E523DQ52638154-23923D55-CE55-460B-8952-B651D8B5E11EQ58542571-4C471B36-78B7-4808-B6EB-0456DE995CF6Q58579872-34C9E626-19E3-4F8B-9BCA-454AB906B63AQ59356484-F1F1433A-AF6E-4F77-BC39-7F9DD9416FC6Q90819622-B611EC13-197F-4561-9A54-CCC5444740CDQ91747094-539D366B-27B6-4FD9-9783-6A086B28551BQ91919544-D2406065-2F7E-4B8D-B800-6D6CE7674A79Q92429671-ED94CD80-5CF9-408A-84B6-453DA0853CACQ92643273-2C8E69B0-B28E-4F15-B9F3-1FFB142487C0Q94448961-5C2974C3-2665-4993-94B1-1DC139AA6B0BQ96345785-E5F2CE4E-E891-4333-92C0-344958698311
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Irina Isakova-Sivak
@ast
Irina Isakova-Sivak
@en
Irina Isakova-Sivak
@es
Irina Isakova-Sivak
@nl
Irina Isakova-Sivak
@sl
type
label
Irina Isakova-Sivak
@ast
Irina Isakova-Sivak
@en
Irina Isakova-Sivak
@es
Irina Isakova-Sivak
@nl
Irina Isakova-Sivak
@sl
prefLabel
Irina Isakova-Sivak
@ast
Irina Isakova-Sivak
@en
Irina Isakova-Sivak
@es
Irina Isakova-Sivak
@nl
Irina Isakova-Sivak
@sl
P106
P1153
23973026600
P21
P31
P496
0000-0002-2801-1508